277 related articles for article (PubMed ID: 21820755)
1. Role of β₁-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy.
Dandel M; Wallukat G; Potapov E; Hetzer R
Immunobiology; 2012 May; 217(5):511-20. PubMed ID: 21820755
[TBL] [Abstract][Full Text] [Related]
2. Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy.
Dandel M; Wallukat G; Englert A; Lehmkuhl HB; Knosalla C; Hetzer R
Eur J Heart Fail; 2012 Dec; 14(12):1374-88. PubMed ID: 22892122
[TBL] [Abstract][Full Text] [Related]
3. Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension.
Dandel M; Wallukat G; Englert A; Hetzer R
Atheroscler Suppl; 2013 Jan; 14(1):203-11. PubMed ID: 23357166
[TBL] [Abstract][Full Text] [Related]
4. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies.
Haberland A; Wallukat G; Dahmen C; Kage A; Schimke I
Circ Res; 2011 Oct; 109(9):986-92. PubMed ID: 21868696
[TBL] [Abstract][Full Text] [Related]
5. The predictive values of beta1-adrenergic and M2 muscarinic receptor autoantibodies for sudden cardiac death in patients with chronic heart failure.
Pei J; Li N; Chen J; Li X; Zhang Y; Wang Z; Zhang P; Cao K; Pu J
Eur J Heart Fail; 2012 Aug; 14(8):887-94. PubMed ID: 22713286
[TBL] [Abstract][Full Text] [Related]
6. Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus.
Dandel M; Englert A; Wallukat G; Riese A; Knosalla C; Stein J; Hetzer R
Atheroscler Suppl; 2015 May; 18():124-33. PubMed ID: 25936316
[TBL] [Abstract][Full Text] [Related]
7. Detection of anti-β1-AR autoantibodies in heart failure by a cell-based competition ELISA.
Holthoff HP; Zeibig S; Jahns-Boivin V; Bauer J; Lohse MJ; Kääb S; Clauss S; Jahns R; Schlipp A; Münch G; Ungerer M
Circ Res; 2012 Aug; 111(6):675-84. PubMed ID: 22811559
[TBL] [Abstract][Full Text] [Related]
8. Are autoantibodies against the beta1-adrenergic receptor markers for dilated cardiomyopathy?
Arndt-Marić R; Nägele H; Schewe G; Kromminga A
Clin Lab; 2010; 56(11-12):519-26. PubMed ID: 21141435
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes.
Christ T; Wettwer E; Dobrev D; Adolph E; Knaut M; Wallukat G; Ravens U
J Mol Cell Cardiol; 2001 Aug; 33(8):1515-25. PubMed ID: 11448139
[TBL] [Abstract][Full Text] [Related]
10. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy.
Störk S; Boivin V; Horf R; Hein L; Lohse MJ; Angermann CE; Jahns R
Am Heart J; 2006 Oct; 152(4):697-704. PubMed ID: 16996841
[TBL] [Abstract][Full Text] [Related]
11. Beta 1-adrenergic receptor-directed autoimmunity as a cause of dilated cardiomyopathy in rats.
Jahns R; Boivin V; Lohse MJ
Int J Cardiol; 2006 Sep; 112(1):7-14. PubMed ID: 16872696
[TBL] [Abstract][Full Text] [Related]
12. Doberman pinschers present autoimmunity associated with functional autoantibodies: A model to study the autoimmune background of human dilated cardiomyopathy.
Wess G; Wallukat G; Fritscher A; Becker NP; Wenzel K; Müller J; Schimke I
PLoS One; 2019; 14(7):e0214263. PubMed ID: 31276517
[TBL] [Abstract][Full Text] [Related]
13. Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study.
Deubner N; Berliner D; Schlipp A; Gelbrich G; Caforio AL; Felix SB; Fu M; Katus H; Angermann CE; Lohse MJ; Ertl G; Störk S; Jahns R;
Eur J Heart Fail; 2010 Jul; 12(7):753-62. PubMed ID: 20494925
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk between anti-beta1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease.
Levin MJ; Hoebeke J
Autoimmunity; 2008 Sep; 41(6):429-33. PubMed ID: 18781468
[TBL] [Abstract][Full Text] [Related]
15. Potential role of antibodies against cardiac Kv channel-interacting protein 2 in dilated cardiomyopathy.
Landsberger M; Staudt A; Choudhury S; Trimpert C; Herda LR; Klingel K; Kandolf R; Schultheiss HP; Kroemer HK; Völker U; Felix SB
Am Heart J; 2008 Jul; 156(1):92-99.e2. PubMed ID: 18585502
[TBL] [Abstract][Full Text] [Related]
16. Non-specific immunoadsorption in patients with dilated cardiomyopathy: mechanisms and clinical effects.
Felix SB; Staudt A
Int J Cardiol; 2006 Sep; 112(1):30-3. PubMed ID: 16860418
[TBL] [Abstract][Full Text] [Related]
17. beta(1)-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy.
Jahns R; Boivin V; Lohse MJ
Trends Cardiovasc Med; 2006 Jan; 16(1):20-4. PubMed ID: 16387626
[TBL] [Abstract][Full Text] [Related]
18. MRI Assessment of Cardiomyopathy Induced by β1-Adrenoreceptor Autoantibodies and Protection Through β3-Adrenoreceptor Overexpression.
Vanhoutte L; Guilbaud C; Martherus R; Bouzin C; Gallez B; Dessy C; Balligand JL; Moniotte S; Feron O
Sci Rep; 2017 Mar; 7():43951. PubMed ID: 28276515
[TBL] [Abstract][Full Text] [Related]
19. Aptamer binding and neutralization of β1-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment.
Haberland A; Wallukat G; Schimke I
Trends Cardiovasc Med; 2011 Aug; 21(6):177-82. PubMed ID: 22814426
[TBL] [Abstract][Full Text] [Related]
20. Anti-beta1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells.
Tutor AS; Penela P; Mayor F
Cardiovasc Res; 2007 Oct; 76(1):51-60. PubMed ID: 17628514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
